

WEBINAR AGENDA

「抗菌薬研究開発促進のためのグローバルコミュニティ形成を目指して」
～欧州抗菌薬インキュベーターINCATE との情報交換会～

Promoting Antibacterial Drug Development through Public-Private Partnership

Information Exchange Meeting with the **INC**ubator for **Antibacterial T**herapies in
Europe (INCATE)

November 26th, 2025 (Online)

Time: 16:00 - 20:45 (JST) | 8:00 - 12:45 (CET)

Aim

This webinar is designed to promote innovation in antimicrobial drug discovery while strengthening and expanding the community of experts in the antibacterial field. It will provide a platform to build an international network that connects academia, startups, industry, and regulators, fostering collaboration to accelerate the development of novel antimicrobial agents at an early stage. With a particular focus on phage therapy, the discussions will showcase pathways to overcome barriers and move promising research into real-world application.

Welcome and Introductions

16:00 – 16:10	Opening Welcome remarks and introduction of objectives	JPMA & INCATE
---------------	--	---------------

Session 1 – Bridging Academia & Startups

16:10 – 16:30 (5 min Q&As)	Development of Lysocin E: An Antibiotic with Outstanding Bactericidal Activity – Current Status of Drug Discovery Research in Infectious Disease – Drug Discovery Startups and Challenges in Bridging the Gap to Clinical Development	Dr. Hiroshi Hamamoto (Silk Strand Pharma, Yamagata University Faculty of Medicine)
16:30 – 16:50 (5 min Q&As)	Introduction to INCATE & tailored support	Mercedes González Moreno, PhD (INCATE)

Session 2 – Promotion of Drug Development in AMR supported by INCATE

16:50 – 17:10 (5 min Q&As)	Invitris – Cell-free protein expression	Patrick Grossman PhD, MBA (CEO Invitris)
17:10 – 17:30 (5 min Q&As)	Justus-Liebig-University Giessen – BamA Inhibitors	Prof. Dr. Till F. Schäberle (Head of Natural Product Research, Justus-Liebig- University Giessen)

17:30 – 17:40	Coffee Break
---------------	---------------------

Session 3 – Challenges in R&D Technology and Regulations for new Drug Modalities – Showcasing Phage Therapy –

17:40 – 18:00
(5 min Q&As) Next-Generation Phage Formulation Design Against MRSA: Opportunities for Collaborative Development

Dr. Hidetomo Iwano

(Laboratory of Veterinary Biochemistry, Department of Veterinary Medicine, Rakuno Gakuen University)

18:00 – 18:20
(5 min Q&As) Phage Drug Discovery: Efficacy, Challenges, and Future Potential

Dr. Kotaro Kiga

(Japan Institute for Health Security)

18:20 – 18:40
(5 min Q&As) Toward the Realization of Phage Therapy

Dr. Hiroki Ando

(CEO Arrowsmith Inc.)

Session 4 – Advice to Key Aspects in Phage Therapy

18:40 – 19:00
(5 min Q&As) Bacteriophages as Pharmaceuticals: From Research and Development to Clinical Application

Ing. Milan Buňata

(Business Director, FAGOFARMA)

19:00 – 19:20
(5 min Q&As) Tackling the Complexities of Bringing Personalized Phage Therapy to the Market

Bob Blasdel, PhD

(Research Director, Inteliphage)

19:20 – 19:40
(5 min Q&As) EU Regulation – New Drug Modalities

Dr. Miriam Fürst-Wilmes

(Project manager, BfArM/DZIF)

19:40 -19:50 **Coffee break**

Session 5 – Panel Discussion: From Discovery to Clinical Application

Chairs: JPMA & INCATE

19:50 – 19:55 Opening Panel Discussion
Moderators: Dr. Hideki Maki (JPMA|Shionogi), Mercedes G. Moreno, PhD (INCATE)

Topic: Bridging from academia and startups to clinical development

Subtopic: Addressing development challenges to boost phage therapy

19:55 – 20:35 **Panelists:** Dr. Hiroshi Hamamoto (Yamagata University)
Dr. Hidetomo Iwano (Rakuno Gakuen University)
Dr. Kotaro Kiga (Japan Institute for Health Security)
Dr. Hiroki Ando (Arrowsmith Inc.)
Dr. Takeo Kohda (Silk Strand Pharma)
Patrick Grossman, PhD, MBA (Invitris)
Prof. Dr. Till F. Schäberle (Justus-Liebig-University Giessen)
Ing. Milan Buňata (FAGOFARMA)
Bob Blasdel, PhD (Inteliphage)
Dr. Miriam Fürst-Wilmes (BfArM)
Derry Mercer, PhD (INCATE)

20:35 – 20:45 **Closing remarks**

JPMA